Involuntary movements
84 results
1 - 84
Involuntary movements - Restless legs and akathisia
- Bruxism
- Essential tremor
Botulinum toxin type A therapy for blepharospasm- Aripiprazole for autism spectrum disorders (ASD)
- Amantadine for dyskinesia in Parkinson's disease
- Frontotemporal lobar degeneration
- Lisuride for levodopa‐induced complications in Parkinson's disease
- Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia
- Monoamine oxidase B inhibitors for early Parkinson's disease
- Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
- Antipsychotics for acute and chronic pain
- Ropinirole versus bromocriptine for levodopa‐induced complications in Parkinson's disease
- Fluphenazine decanoate (depot) and enanthate for schizophrenia: Cochrane systematic review
- Trihexyphenidyl for dystonia in cerebral palsy
- Lisuride versus bromocriptine for levodopa‐induced complications in Parkinson's disease
- Fluphenazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia
- Anticholinergic medication for antipsychotic‐induced tardive dyskinesia
- Pergolide versus bromocriptine for levodopa-induced complications in Parkinson's disease: Cochrane systematic review
- Aripiprazole alone or in combination for acute mania
- Epilepsy in children
- Surgical interventions for infantile nystagmus syndrome
- Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia
- Antiepileptic drugs for the primary and secondary prevention of seizures after subarachnoid haemorrhage
- Physical therapy for Bell's palsy (idiopathic facial paralysis): Cochrane systematic review
- Cabergoline for levodopa‐induced complications in Parkinson's disease
- Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease: Cochrane systematic review
- Fluphenazine (oral) versus placebo for schizophrenia
- Tremor
- Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease
- Trifluoperazine versus placebo for schizophrenia: Cochrane systematic review
- Non‐antipsychotic catecholaminergic drugs for antipsychotic‐induced tardive dyskinesia
- Gamma‐aminobutyric acid agonists for antipsychotic‐induced tardive dyskinesia
- Pergolide for levodopa-induced complications in Parkinson's disease: Cochrane systematic review
- Cabergoline versus bromocriptine for levodopa‐induced complications in Parkinson's disease
- Pramipexole for levodopa‐induced complications in Parkinson's disease
- Vitamin E for antipsychotic‐induced tardive dyskinesia
- Benzodiazepines for antipsychotic‐induced tardive dyskinesia
- Transcranial direct current stimulation (tDCS) for idiopathic Parkinson's disease
- Cholinergic medication for antipsychotic‐induced tardive dyskinesia
- Clinical assessment of memory impairment
- Aripiprazole alone or in combination for acute mania: Cochrane systematic review
- Botulinum toxin type A versus anticholinergics for cervical dystonia
- Calcium channel blockers for antipsychotic‐induced tardive dyskinesia
- Deep brain stimulation for dystonia
- Ropinirole for levodopa-induced complications in Parkinson's disease: Cochrane systematic review
- Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia
- Vigabatrin add‐on therapy for drug‐resistant focal epilepsy
- Obsessive-compulsive disorder (OCD) in children
- Antipsychotics for acute and chronic pain in adults
- Botulinum toxin type A therapy for cervical dystonia
- Botulinum toxin type A versus botulinum toxin type B for cervical dystonia
- Pharmacotherapy for sleep bruxism
- Withdrawal versus continuation of long‐term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia
- Schizophrenia
- Rehabilitation of patients with spinal cord injury, and problems associated with such injury